Scoop: Corporate development chief hits the exit at Biogen as aducanumab jitters roll on
Michel Vounatsos has lost another member of his executive team.
Less than 2 years after Daniel Karp was hired on as the EVP of corporate development — where he ran the strategy and BD teams — he’s now hitting the exit as the company finds itself at a momentous crossroads.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.